Loading clinical trials...
Loading clinical trials...
Phase II Study of the Predictive Value of the Expression of Tumoral MGMT With Respect to the Therapeutic Response of Fotemustine in Patients With Metastatic Malignant Melanoma
Conditions
Interventions
fotemustine
Locations
1
France
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France
Start Date
August 8, 2003
Primary Completion Date
August 31, 2008
Completion Date
August 31, 2008
Last Updated
February 14, 2025
NCT06956690
NCT05649683
NCT00003641
NCT03543969
NCT04079166
NCT05492682
Lead Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions